Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

• US 6,548,491 B2
• Filed: 05/31/2001
• Issued: 04/15/2003
• Est. Priority Date: 12/24/1997
• Status: Expired due to Term

• Current Assignee: SRI International, Inc.
• Original Assignee: SRI International, Inc.
• Inventors: Tanabe, Masato, Peters, Richard H., Chao, Wan-Ru, Jong, Ling
• Primary Examiner(s): Badio, Barbara P.
• Application Number:
  US09/872,825
• Publication Number:
  US 20020032180A1
• Time in Patent Office: 684 Days
• Field of Search: 552/530, 552/531, 514/169, 514/182
• US Class Current: 514/182
• CPC Class Codes: A61K 9/02 Suppositories; Bougies; Bases therefor; Ovulesapparatus for making A61J3/08; devices for introducing into the body A61M31/00
• CPC Class Codes: C07J 41/0072 the A ring of the steroid being aromatic
• CPC Class Codes: C07J 41/0077 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
• CPC Class Codes: C07J 43/003 not condensed

Abstract

Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5(10)-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5(10)-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

Claims

1. A 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

p is an integer in the range of 0 to 6;

R²⁹ and R³⁰ are selected from the group consisting of hydrogen, lower alkyl, and halogenated lower alkyl, or are linked together to form a heterocycloalkyl ring, with the proviso that R²⁹ and R³⁰ are not both hydrogen; and

L is a five- or six-membered cyclic moiety that may or may not be aromatic, optionally containing 1 to 4 heteroatoms selected from the group consisting of N, O and S and combinations thereof, and optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogenated alkyl, alkenyl, and alkoxy, carboxyl, hydroxy, amino, nitro, cyano, and halogen.

7. A pharmaceutical composition for administering an anti-estrogenic agent, comprising a therapeutically effective amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6, in combination with a pharmaceutically acceptable carrier.

8. A method for treating an individual with an estrogen-dependent disorder, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6.

9. The method of claim 8, wherein the estrogen-dependent disorder is breast cancer.

10. The method of claim 8, wherein the estrogen-dependent disorder is uterine cancer.

11. A method for treating an individual with an non-estrogen dependent cancer, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6.

12. The method of claim 11, wherein the cancer is multiple drug-resistant.

13. A method for increasing bone mass in the body of a mammalian individual, comprising administering to the individual an effective bone mass increasing amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6.

14. A method for inhibiting bone loss in the body of a mammalian individual, comprising administering to the individual an effective bone loss inhibiting amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6.

20. A method for treating osteoporosis in the body of a mammalian individual, comprising administering to the individual a therapeutically effective amount of the compound of any one of claims 1, 2, 3, 4, 5 or 6.

2. A 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

p is an integer in the range of 0 to 6;

R²⁹ and R³⁰ are lower alkyl or are linked together to form a heterocycloalkyl ring; and

Q¹, Q², Q³ and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

3. A compound having the formula (Ia)

wherein:

j is an integer in the range of 0 to 5 inclusive;

p is an integer in the range of 0 to 6 inclusive;

when r2 is present, R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl, and when r2 is absent, R¹ is hydrogen, alkyl or halogen;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkenyl, aryl, alkaryl, —

ONO₂, —

OR¹³ and —

SR¹³ wherein R¹³ is alkyl, acyl or aryl;

R³ is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkenyl, aryl, alkaryl, cyano, —

OR¹³ and —

SR¹³ wherein R¹³ is alkyl, acyl, or aryl;

as defined previously;

R⁴ is hydrogen or lower alkyl;

R⁵ is selected from the group consisting of hydrogen, lower alkoxy, halogen, cyano, —

CH₂CH═

CH₂, —

CHO, —

NR¹⁴R¹⁵ and —

(CH₂)NR¹⁴R¹⁵ wherein R¹⁴ and R¹⁵ may be the same or different and are either hydrogen or alkyl, or together form a five- or six-membered cycloalkyl group optionally containing an additional nitrogen heteroatom;

R⁶ is selected from the group consisting of hydrogen, alkyl, acyl, —

C(O)-aryl, —

C(O)-alkyl and —

SO₂NH₂;

R⁷ is selected from the group consisting of hydrogen, halogen, —

NO₂, —

CHO, —

CH₂CH═

CH₃, —

NR¹⁶R¹⁷ and —

(CH₃)NR¹⁶R¹⁷ wherein R¹⁶ and R¹⁷ may be the same or different and are either hydrogen, alkyl or acetyl;

R⁸ is selected from the group consisting of hydrogen, hydroxyl, —

OR¹⁸ and —

SR¹⁸ wherein R¹⁸ is lower alkyl, lower acyl or aryl;

R¹⁰ is methyl or ethyl;

R²⁹ and R³⁰ are selected from the group consisting of hydrogen, lower alkyl and halogenated lower alkyl, or are linked together to form a five- or six-membered heterocycloalkyl ring, with the proviso that when R³ is hydrogen, then R²⁹ and R³⁰ are not both hydrogen; and

L is a five- or six-membered cyclic moiety that may or may not be aromatic, optionally containing 1 to 4 heteroatoms selected from the group consisting of N, O and S and combinations thereon and optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkoxy, halogenated alkyl, alkenyl, and alkoxy, carboxyl, hydroxy, amino, nitro, cyano, and halogen, or a pharmaceutically acceptable salt or ester thereof.

4. The compound of claim 3, having the structural formula (Ib)

wherein R²⁹ and R³⁰ are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring, and Q¹, Q², Q³ and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

5. A chemical compound selected from the group consisting of:

(E)-3-hydroxy-21-(2′

-hydroxylethylamino)-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[3′

-(N,N-dimethylamino)-propylamino]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-{2-[2″

-(N,N-dimethylamino)ethoxy]-ethoxy}-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[3′

-(N,N-dimethylamino)propoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(N,N-dimethylamino)-ethanethio]-19-norpregna-1,3,5(10),17(20-tetraene, (E)-3-hydroxy-21-[2′

-(pyrrolidinyl)ethoxy]-19-norpregna-1,3,5(10), 17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(morpholinyl)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(piperazinyl)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

-methyl-21-[2′

-(N,N-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-2-methoxy-21-[2′

-(N,N-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

-methyl-21-[2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(N,N-dimethylamino)-2-propoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (Z)-3-hydroxy-21-[2′

-(N,N-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-(N-methyl-3-(R,S)-pyrrolidinoxy)-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[N-methyl-2(S)-pyrrolidinylmethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (K)-3-hydroxy-2-N,N-dimethylaminomethyl-21-[2′

-(N′

,N′

-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

-methyl-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (K)-3-hydroxy-7α

-methyl-21-{2′

-[2″

-(N,N-dimethylamino)-ethoxy]ethoxy}-19-norpregna-1,3,5(10),17(20)-tetraene, (E)- and (Z)-3-hydroxy-7α

-methyl-21-[2′

-(pyrrolidinyl)methoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

- and 7β

-ethyl-21-[2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (Z)-3-tetrahydropyranyloxy-20-methyl-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-tetrahydropyranyloxy-20-methyl-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (Z)-3-hydroxy-20-methyl-21-]2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-20-methyl-21-[2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, and 21-(2′

-N,N-dimethylaminoethoxy)-[17(20)E]-19-norpregna-1,3,5(10),18(20)-tetraene-3-O-sulfamate.

6. A chemical compound selected from the group consisting of:

(E)-3-hydroxy-21-[2′

-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

-methyl-21-[2′

-(N,N-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-2-methoxy-21-[2′

-(N,N-dimethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, the citrate of (E)-3-hydroxy-7α

-methyl-21-[2′

-(N,N-diethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

-methyl-21-{2′

-[2″

-(N,N-dimethylamino)-ethoxy]ethoxy}-19-norpregna-1,3,5(10),17(20)-tetraene, (E)- and (Z)-3-hydroxy-7α

-methyl-21-[2′

-(pyrrolidinyl)methoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, (E)-3-hydroxy-7α

- and 7β

-ethyl-21-[2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, and (E)-3-hydroxy-20-methyl-21-[2′

-(N,N-diethylamino)-ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene.

15. A method for lowering serum cholesterol in the body of a mammalian individual, comprising administering to the individual an effective serum cholesterol lowering amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.

16. A method for inhibiting a pulmonary hypertensive disease, comprising administering to an individual in need of such treatment a therapeutically effective amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.

17. A method for inhibiting skin atrophy, comprising prophylactically administering to a postmenopausal female individual an effective amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.

18. A method for inhibiting vaginal atrophy, comprising prophylactically administering to a postmenopausal female individual an effective amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.

19. A method for inhibiting an estrogen-dependent CNS disorder, comprising prophylactically administering to a postmenopausal female individual an effective amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.

21. A method for inhibiting a CNS disorder in a postmenopausal human female, comprising administering to the individual a therapeutically effective amount of a 17-desoxy-1,3,5(10)-estratriene containing the molecular moiety

at the C-17 position of the estratriene nucleus, wherein:

j is an integer in the range of 0 to 5 inclusive;

R²¹ is hydrocarbyl including at least one oxygen atom, sulfur atom, and/or nitrogen atom in the form of an —

O—

, —

S—

, —

NH—

or —

N(alkyl)-linkage, and optionally including additional substituents selected from the group consisting of hydroxyl, oxo, alkoxy, amino, substituted amino, halogeno, aryl, heteroaryl and heterocycloalkyl; and

R²² is hydrogen or alkyl, or,

when m is 0, R²¹ and R²² may be linked to form a five-or six-membered cyclic moiety which may or may not be aromatic, containing 0 to 3 heteroatoms selected from the group consisting of N, O and S, and substituted with 0 to 4 substituents selected from the group consisting of alkyl, alkenyl, alkynyl and alkoxy.